XML 44 R28.htm IDEA: XBRL DOCUMENT
v3.23.3

Revenue from Contracts with Customers (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2023
Schedule of Contract Assets and Contract Liabilities | Total contract assets at September 30, 2023 were as follows:
(In thousands) |  | Contract Assets |
Contract assets at December 31, 2022 |  | $ | 8,929 |
Additions |  |  | 12,881 |
Transferred to receivables, net |  |  | (19,044 | )
Contract assets at September 30, 2023 |  | $ | 2,766 |
Total contract liabilities at September 30, 2023 were as follows:
(In thousands) |  | Contract Liabilities |
Contract liabilities at December 31, 2022 |  | $ | 10,701 |
Additions |  |  | (931 | )
Amounts recognized into revenue |  |  | (4,794 | )
Contract liabilities at September 30, 2023 |  | $ | 4,976 |
Product sales, net |
Schedule of Disaggregation of Revenues | During the three and nine months ended September 30, 2023 and 2022, the Company recorded product sales, net, as follows:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(In thousands) |  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
VIVITROL |  | $ | 99,305 |  |  | $ | 96,534 |  |  | $ | 298,035 |  |  | $ | 277,493 |
ARISTADA and ARISTADA INITIO |  |  | 81,834 |  |  |  | 75,719 |  |  |  | 244,320 |  |  |  | 222,826 |
LYBALVI |  |  | 50,683 |  |  |  | 27,127 |  |  |  | 135,671 |  |  |  | 61,116 |
Total product sales, net |  | $ | 231,822 |  |  | $ | 199,380 |  |  | $ | 678,026 |  |  | $ | 561,435 |
Manufacturing and royalty revenues |
Schedule of Disaggregation of Revenues | During the three and nine months ended September 30, 2023 and 2022, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:
|  | Three Months Ended September 30, 2023 |  |  | Nine Months Ended September 30, 2023 |
(In thousands) |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |  |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |
Long-acting INVEGA products(1) |  | $ | — |  |  | $ | 76,109 |  |  | $ | 76,109 |  |  | $ | — |  |  | $ | 410,910 |  |  | $ | 410,910 |
VUMERITY |  |  | 9,733 |  |  |  | 24,828 |  |  |  | 34,561 |  |  |  | 32,751 |  |  |  | 62,979 |  |  |  | 95,730 |
RISPERDAL CONSTA |  |  | 14,732 |  |  |  | 151 |  |  |  | 14,883 |  |  |  | 30,049 |  |  |  | 957 |  |  |  | 31,006 |
Other |  |  | 16,157 |  |  |  | 7,403 |  |  |  | 23,560 |  |  |  | 48,160 |  |  |  | 22,082 |  |  |  | 70,242 |
|  | $ | 40,622 |  |  | $ | 108,491 |  |  | $ | 149,113 |  |  | $ | 110,960 |  |  | $ | 496,928 |  |  | $ | 607,888 |
|  | Three Months Ended September 30, 2022 |  |  | Nine Months Ended September 30, 2022 |
(In thousands) |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |  |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |
Long-acting INVEGA products(1) |  | $ | — |  |  | $ | 26,737 |  |  | $ | 26,737 |  |  | $ | — |  |  | $ | 90,439 |  |  | $ | 90,439 |
VUMERITY |  |  | 5,584 |  |  |  | 20,666 |  |  |  | 26,250 |  |  |  | 22,629 |  |  |  | 60,386 |  |  |  | 83,015 |
RISPERDAL CONSTA |  |  | 8,380 |  |  |  | 1,848 |  |  |  | 10,228 |  |  |  | 32,529 |  |  |  | 5,516 |  |  |  | 38,045 |
Other |  |  | 3,265 |  |  |  | (13,539 | ) |  |  | (10,274 | ) |  |  | 26,472 |  |  |  | 5,466 |  |  |  | 31,938 |
|  | $ | 17,229 |  |  | $ | 35,712 |  |  | $ | 52,941 |  |  | $ | 81,630 |  |  | $ | 161,807 |  |  | $ | 243,437 |
(1) “Long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate).

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=alks_ManufacturedProductAndRoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |